Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 315-321

  Chamberlain, Marc C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Hydroxyurea; Recurrent high grade meningioma; Surgery and radiation refractory

Indexed keywords

HYDROXYUREA; IRINOTECAN; OCTREOTIDE; RECOMBINANT ALPHA INTERFERON; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CANCER SURGERY; CLINICAL ARTICLE; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; KARNOFSKY PERFORMANCE STATUS; LYMPHOCYTOPENIA; MALE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENT CANCER; REOPERATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SINGLE DRUG DOSE; STEREOTACTIC PROCEDURE; STEREOTACTIC RADIOSURGERY; STEREOTACTIC RADIOTHERAPY; SURVIVAL TIME; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT RESPONSE; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOSURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXYUREA; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES;

EID: 84863566713     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0741-z     Document Type: Article

References (30)

1. Norden AD, Drappatz J, Wen PY (2009) Advances in meningioma therapy. Curr Neurol Neurosci Rep 9(3):231-240
2. Sioka C, Kyritis AP (2009) Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 92:1-6
3. Simon M, Bostrom JP, Hartmann C (2007) Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60(5):787-798
4. McMullen KP, Stieber VW (2004) Meningioma: current treatment options and future directions. Curr Treat Options Oncol 5:499-509
5. Rockhill J, Mrugala M, Chamberlain MC (2007) Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus 23:E1
6. Goldsmith B, McDermott MW (2006) Meningioma. Neurosurg Clin N Am 17:111-120
7. Chamberlain MC, Barnholtz-Sloan J (2011) Medical treatment of recurrent meningiomas. Expert Rev Neurother 11(10):1425-1432
8. Brem SS, Bierman PJ, Brem H et al (2011) Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw 9(4):352-400
9. Schrell UM, Ritting MG, Anders M et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840-844
10. Schrell UM, Ritting MG, Anders M et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86(5):845-852
11. Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49(2):165-170
12. Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended followup. Br J Neurosurg 18:495-499
13. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341-346
14. Rosenthal MA, Ashley DL, Cher L (2002) Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9(2):156-158
15. Hahn BM, Schrell UMH, Sauer R et al (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157-165
16. Loven D, Hardoff R, Sever ZB et al (2004) Non-resectable slowgrowing meningiomas treated by hydroxyurea. J Neurooncol 67:221-226
17. Nayak L, Iwamoto F, Kaley T (2011) Atypical and anaplastic meningioma treated with bevacizumab. Neurology 76:A96 (abstract P02.011)
18. Kaley TJ, Wen PY, Schiff D et al (2010) Phase II Trial of Sunitinib (SU011248) for recurrent meningioma. Neuro Oncol 12(s4):iv75-iv76
19. Grimm SA, Chamberlain MC, Chandler J et al (2011) Aphase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. Proceeding American Society of Clinical Oncology. Chicago, IL. May 2010. J Clin Oncol 29(15S):151s (abstract #2046)
20. Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907
21. Wen PY, Yung WK, Lamborn KR et al (2009) Phase II study of imatinib methylate (Gleevec) for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 11(6):853-860
22. Norden AD, Raizer JJ, Abrey LE et al (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211-217
23. Hammond S, Norden A, Drappatz J et al (2011) Phase II study of monthly Pasireotide (SOM230C) for recurrent or progressive meningioma. J Clin Oncol 29(15S):150s (abstract #2040)
24. Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with sandostatin. Neurology 69: 969-973
25. Chamberlain MC, Glantz MJ (2008) α-Interferon for recurrent WHO grade I intracranial meningiomas. Cancer 113:2146-2151
26. Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory WHO Grade 1 meningioma. J Neurooncol 104(3):765-771
27. Grunberg SM, Rankin C, Townsend J et al (2001) Phase II double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 20:56a (#222)
28. Chamberlain MC (1996) Malignant meningiomas: adjunct combined modality therapy. J Neurosurg 84:733-736
29. Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase 2 studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
30. Wen P, Macdonald DR, Reardon DA et al (2009) Proposal for an updated response assessment criteria for high-grade gliomas: radiology assessment for neuro-oncology: working group. J Clin Oncol 28:1963-1972